Approved in 2025 for hormone receptor-positive, HER2-negative breast cancer, it demonstrates efficacy in tumors with high TROP2 expression.130 The cleavable linker and membrane-permeable payload facilitate a bystander effect, killing adjacent tumor cells regardless of TROP2 expression heterogeneity. This evidence concerns the gene TACSTD2 and breast carcinoma.